New HIV Combination Therapy for People on Biktarvy
Treatments studied
Part of Infections clinical trials.
This study tests a new HIV medication (GS-3242) combined with lenacapavir against your current Biktarvy regimen. Both are all-oral treatments for people whose HIV is well-controlled.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your HIV viral load must be undetectable (below 50 copies) for at least 6 months before joining and at your screening visit
- You must have been taking Biktarvy (or its generic equivalent) consistently for at least 6 months
- You cannot have any resistance patterns to the new medication GS-3242 that would make it ineffective
- You have never taken GS-3242 or lenacapavir before
- You have not experienced treatment failure (viral load rebound) on any integrase inhibitor-based HIV regimen
- You have never received long-acting injectable HIV medications like cabotegravir or rilpivirine injections
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new injectable HIV treatment (GS-3242 plus lenacapavir) compared to the daily pill Biktarvy for people just starting HIV therapy. If you qualify, you would receive shots every few weeks instead of taking a daily pill.
This trial provides continued access to Biktarvy (B/F/TAF) for children and adolescents who completed a previous Gilead HIV study. It ensures they can keep taking the medication without interruption.
This trial tests the medication Biktarvy (bictegravir, emtricitabine, and tenofovir alafenamide) for people with HIV who have stopped taking their antiretroviral therapy (ART) for at least 12 weeks and are ready to restart treatment. It aims to see how well the medication works when restarting care.
This study measures the “hidden” HIV reservoir in the body and how it relates to blood levels of antiretroviral medicines. It may help doctors better understand why HIV can remain even when the virus is controlled.
This trial tests a new combination of three medications, lenacapavir, teropavimab, and zinlirvimab, for people with HIV who currently have undetectable virus levels on a stable oral treatment. The goal is to see if these drugs can keep the virus suppressed, possibly allowing a simpler treatment plan.
This trial tests a new oral HIV medication (VH4524184) in people who have never taken HIV treatment before. It looks at how well the drug controls the virus and how safe it is.
Hear when a new HIV-1-infection trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.